Stempeutics Research

What Stempeutics Research does

Stempeutics Research Pvt Ltd is a Bangalore-based clinical-stage and commercial-stage life sciences company founded in 2006 by Manipal Education and Medical Group (MEMG). The company develops and commercializes novel therapeutics based on adult stem cells, with its core focus on Stempeucel®, a pooled, allogeneic, off-the-shelf Mesenchymal Stromal Cell (MSC) therapy produced through a proprietary patented process that combines bone marrow-derived cells from multiple healthy adult donors to reduce inter-donor variability and deliver consistent clinical outcomes. The company operates an India-first, Global-next commercial model with a 51-100 person organization and R&D/GMP manufacturing based at Kemwell Biopharma's DCGI-approved Bangalore facility.

Stempeucel® has received DCGI commercial approval for Critical Limb Ischemia (CLI) due to Buerger's Disease and atherosclerotic PAD in August 2020 — making it the first allogeneic cell therapy approved for commercial use in India and the first stem cell product globally approved for CLI — and for Knee Osteoarthritis (OA) in 2023. Additional indications including Diabetic Foot Ulcer (Phase 3), Peri-anal Fistula in Crohn's Disease (Phase I/II), and Chronic Low Back Pain due to disc degeneration (pre-clinical/Phase 1) are in development. A complementary Stempeucare® bio-cosmetic portfolio (Cutisera® skincare, Trichosera® haircare, Perioptisera® under-eye care) is also DCGI-approved and approved for export, leveraging the same proprietary conditioned-medium process.

Stempeutics monetizes through multiple revenue streams: pharmaceutical product sales via Indian channel partners (Cipla distributes CLI/DFU as Regenacip® and OA as Ciplostem; Alkem distributes OA as StemOne®), licensing and partnership revenue for international markets (MEDINET Japan option license signed October 2025 for CLTI), co-development and GMP manufacturing services through Kemwell Biopharma, and consumer sales of bio-cosmetics. The company holds 50+ granted patents across 18 countries, has received EMA ATMP classification and Orphan Drug Designation for CLI due to Buerger's Disease, ISO 9001:2015 certification, and has completed regulatory engagement with US FDA (Pre-IND), EMA (Scientific Advisory), and PMDA Japan (preliminary consultation).

Name

Stempeutics Research

Legal name

Stempeutics Research Pvt Ltd

Website

https://stempeutics.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

Stempeutics Research is a Bangalore-based biotech commercializing Stempeucel®, a pooled allogeneic MSC therapy approved in India for Critical Limb Ischemia and Knee Osteoarthritis, distributed via Cipla and Alkem partnerships, with a complementary DCGI-approved bio-cosmetic portfolio and active ex-India licensing efforts.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Stem Cell–Based Regenerative Therapies (HLAAAGAA), Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO)

Keywords

• Stem cell therapy
• Allogeneic MSC therapy
• Regenerative medicine
• Cell therapy products
• Bio-cosmetic products

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others, Marketing or Sales

Revenue model

1. Pharmaceutical/Therapeutic Product Sales: Revenue from commercial sales of DCGI-approved Stempeucel® products in India through marketing partners Cipla (CLI and DFU products under brand Regenacip) and Alkem (Knee Osteoarthritis product under brand StemOne). Products are administered in clinical/hospital settings as single-dose intra-articular or intra-arterial treatments.
2. Bio-Cosmetic Product Sales: Revenue from commercially approved bio-cosmetic products including Cutisera® (skincare), Trichosera® (haircare), and Perioptisera® (under-eye care). These are sold as topical consumer products containing stem cell-derived growth factors and cytokines. Products are approved for marketing and export by regulatory authorities in India.
3. Licensing and Partnership Revenue: Revenue from licensing Stempeucel® technology and product rights to international partners. MEDINET Japan signed an Option License Agreement for Stempeucel® product for Chronic Limb Threatening Ischemia (CLTI) indication for Japan Territory. The company is seeking partnerships for global markets outside India.
4. Co-Development and Manufacturing Services: Revenue from co-development partnerships such as the agreement with Kemwell Biopharma for global development and commercialization of stem cell therapeutics. Kemwell operates GMP manufacturing and R&D facilities for Stempeutics products.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

Stempeutics Research develops and commercializes novel therapeutics based on adult stem cells. Its flagship product Stempeucel® is an off-the-shelf, pooled, allogeneic Mesenchymal Stromal Cell (MSC) therapy derived from bone marrow of healthy adult volunteers, with DCGI approvals in India for Critical Limb Ischemia (marketed as Regenacip®) and Knee Osteoarthritis (marketed as StemOne®). The company also offers a DCGI-approved bio-cosmetic portfolio (Cutisera®, Trichosera®, Perioptisera®) and pursues global expansion through licensing partnerships.

Product overview

Stempeutics Research is a life science company developing and commercializing novel therapeutics based on adult stem cells. Its core product platform is Stempeucel®, an off-the-shelf, pooled, allogeneic MSC therapy with DCGI approval for Critical Limb Ischemia and Knee Osteoarthritis, with additional therapeutic indications (Diabetic Foot Ulcer, Peri-anal Fistula, Chronic Low Back Pain) in clinical development. The company also offers a complementary bio-cosmetics portfolio under the Stempeucare™ brand, including Cutisera® (skincare), Trichosera® (haircare), and Perioptisera® (under-eye care), all DCGI-approved. Therapeutic products are marketed in India through partnerships with Cipla (Regenacip® for CLI) and Alkem (StemOne® for OA), while the company seeks global commercialization partnerships.

Differentiator

Problem solved

Functional benefit

Brands

• Stempeucel: Flagship allogeneic MSC therapy product for Critical Limb Ischemia, Knee Osteoarthritis, and other indications under development.
• Stempeucare
• Perioptisera
• Trichosera
• Cutisera

Products and services

• Stempeucel® Critical Limb Ischemia (CLI) Allogeneic pooled MSC therapy administered as a single-dose intra-arterial injection for Critical Limb Ischemia due to Buerger's Disease and atherosclerotic Peripheral Arterial Disease. Works through anti-inflammatory, immunomodulatory, and angiogenic properties to improve blood flow and prevent limb amputation. Marketed in India as Regenacip® by Cipla.
• Stempeucel® Knee Osteoarthritis Allogeneic pooled MSC therapy administered as single-dose intra-articular injection for Grade 2-3 Knee Osteoarthritis. Exerts anti-inflammatory, immunomodulatory, and chondrogenic properties to reduce joint pain, regenerate/maintain cartilage, and stall disease progression. Marketed in India as StemOne® by Alkem and as Ciplostem by Cipla.
• Stempeucel® Diabetic Foot Ulcer (DFU) Phase 3 clinical-stage product candidate utilizing anti-inflammatory, angiogenic, and wound healing properties of pooled allogeneic MSCs for treatment of non-healing Diabetic Foot Ulcers. Targeted at India's 77 million diabetes cases and broader global diabetic population.
• Stempeucel® Peri-anal Fistula (Crohn's Disease) Phase I/II clinical-stage product candidate for treatment of Peri-anal Fistula due to Crohn's disease. Leverages immunoregulatory activity of pooled allogeneic MSCs to reduce inflammation and enable healing of fistula tract tissues.
• Stempeucel® Chronic Low Back Pain (Disc Degeneration) Pre-clinical/early-stage product candidate for treatment of chronic low back pain caused by disc degeneration in patients who have exhausted conservative treatment options and wish to avoid invasive spinal fusion surgery.
• Cutisera® DCGI-approved anti-aging skincare serum developed from adult stem cell-derived growth factors and cytokines. Non-greasy, intensive, translucent liquid that promotes firm, well-moisturized, and clearer skin with reduced blemishes and fine lines. Targeted at premium bio-cosmetic consumers seeking science-backed anti-aging skincare.
• Trichosera® DCGI-approved novel hair serum prepared from stem cell bio-active medium. Promotes scalp hair growth, reduces hair fall, and improves hair density. Targeted at consumers experiencing hair thinning or hair fall.
• Perioptisera® DCGI-approved under-eye serum containing stem cell-derived bioactive medium. Reduces under-eye dark circles, eye bags, and rehydrates and soothes under-eye skin. Targeted at consumers with visible under-eye concerns.
• Multisera Facial Bundle Pipeline bio-cosmetic product bundle containing face wash, face scrub, day cream, and night cream derived from novel stem cell-derived conditioned medium. Targeted at consumers seeking a complete stem-cell-based facial care regimen.

Quantifiable outcome

• Statistically significant outcomes demonstrated in CLI Phase 2 trial (90 patients) for all critical endpoints including amputation-free survival, pain-free walking distance, and ulcer healing
• +7 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered flagship and core.

• Cipla (Ciplostem OA Launch)flagshipChannel Partner/ Reseller/ Distributor · 2 June 2026Cipla partnered with Stempeutics to launch Ciplostem, a stem-cell therapy for Grade II-III knee osteoarthritis, approved by DCGI. The single-dose intra-articular treatment targets India's 48 million OA patients. Ciplostem represents a second OA branded product alongside Alkem's StemOne, expanding Cipla's role in the osteoarthritis market.
• MEDINET JapanflagshipChannel Partner/ Reseller/ Distributor · 1 October 2025MEDINET Japan signed an Option License Agreement with Stempeutics India for Stempeucel® product for Chronic Limb Threatening Ischemia (CLTI) indication for Japan Territory. This represents a key step in Stempeutics' global expansion strategy, targeting the Japanese market. Stempeutics has also completed a preliminary consultation meeting with PMDA Japan.
• Alkem (Co-Development)coreStrategic or Co-development Partner · 1 March 2022Stempeutics signed a co-development agreement with Alkem for its stem cell therapy product Stempeucel® for treating Osteoarthritis of the knee, in addition to the existing marketing agreement. This deepens the partnership beyond distribution to collaborative product development.
• AlkemcoreChannel Partner/ Reseller/ Distributor · 1 August 2021Stempeutics signed a marketing agreement with Alkem for distributing Knee Osteoarthritis product for India territory. The OA product is marketed under the brand name 'StemOne'. Alkem is a major Indian pharmaceutical company with strong presence in the orthopaedics and musculoskeletal segment.
• Kemwell BiopharmacoreStrategic or Co-development Partner · 1 July 2019Stempeutics partnered with Kemwell for global development and commercialization of stem cell therapeutics. Kemwell operates GMP manufacturing and R&D facilities at Nelamangala, Bangalore for Stempeutics. Kemwell's facility is DCGI-approved for clinical trial manufacturing (Form 29) and commercial manufacturing (Form 28) of cell/stem cell derived products. Kemwell is led by Chairman & CEO Anurag Bagaria, member of Stempeutics Board of Directors.
• CiplacoreChannel Partner/ Reseller/ Distributor · 1 May 2018Stempeutics signed a marketing agreement with Cipla for distributing CLI and DFU products for India territory. The CLI product is marketed under the brand name 'Regenacip' (Regenacip 200M injection). Cipla is one of India's largest pharmaceutical companies with extensive hospital and specialist physician networks. Cipla also partnered with Stempeutics to launch Ciplostem, a stem-cell therapy for Grade II-III knee osteoarthritis, approved by DCGI.
• Manipal Education and Medical Group (MEMG)coreStrategic or Co-development Partner · 1 January 2006Stempeutics was founded by Manipal Education and Medical Group (MEMG) in 2006. MEMG is the parent organization providing strategic direction and founding leadership. Dr. Ranjan Pai, Chairman of MEMG, serves as the Founder. MEMG established Stempeutics as part of its life sciences portfolio alongside Manipal Hospitals and other healthcare ventures.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Athersys / Healios: MultiStem is an off-the-shelf, bone marrow-derived allogeneic multipotent progenitor cell therapy being advanced by Healios in Japan for stroke and ARDS, and by Athersys for AMI — directly comparable platform and indication adjacency to Stempeucel®.
• Mesoblast: Australia/US-listed allogeneic cell therapy company developing bone marrow-derived MSC products (remestemcel-L, Revascor) for inflammatory and cardiovascular indications including CLI — the most direct global comparator to Stempeucel®'s mechanism and indications.
• TiGenix (Takeda): Developed darvadstrocel (Cx601), an allogeneic adipose-derived MSC therapy approved in Europe for complex perianal fistulas in Crohn's disease — the exact same indication for which Stempeutics' PAF program is in Phase I/II, making it the closest indication-overlap comparator.
• Vericel: US commercial-stage cell therapy company marketing MACI (autologous chondrocytes for cartilage repair) and ixmyelocel-T — a relevant peer on the orthobiologics/cartilage regeneration side of Stempeucel®'s OA indication.
• Regrow Biosciences: India-based competitor developing autologous and allogeneic cell therapy products (e.g., Ossron™ for bone regeneration, Chondron+ for cartilage) — directly comparable India-headquartered cell therapy peer targeting similar orthobiologics and degenerative disease indications.
• Pluristem Therapeutics: Israel-based developer of PLacenta-eXpanded (PLX) allogeneic cell therapy products for CLI, muscle injury, and hematopoietic recovery — comparable allogeneic, off-the-shelf cell therapy model targeting peripheral ischemia indications.

Regional players

• MEDINET: Japan-based cell therapy services and product company that signed the October 2025 Option License Agreement with Stempeutics for CLTI in Japan — operates as both a regional partner and an emerging regional cell therapy peer in the Japanese market.

Emerging players

• Eyestem Research: India-based early-stage cell therapy company developing iPSC-derived retinal pigment epithelium therapies — an emerging domestic peer advancing the India cell therapy ecosystem and potentially future competitor on platform technology.

Broad incumbents

• Lonza Group: Global contract development and manufacturing organization with a leading cell and gene therapy services franchise — comparable in manufacturing/processing capability that Stempeutics currently accesses through Kemwell Biopharma, and a likely alternative as Stempeutics scales.
• Catalent: Major CDMO with established cell therapy manufacturing infrastructure (Paragon, MaSTheraCell) — a broad incumbent in the cell therapy services ecosystem where Stempeutics' outsourced manufacturing sits.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/stempeutic
• LinkedInlinkedin.com/company/stempeutics-research-pvt--ltd-
• Facebookfacebook.com/stempeuticsresearch

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stempeutics Research